

Chikungunya Fever R&D Pipeline Analysis Report, Q4 2020

<https://marketpublishers.com/r/C9054E303A88EN.html>

Date: October 2020

Pages: 138

Price: US\$ 2,199.00 (Single User License)

ID: C9054E303A88EN

Abstracts

Chikungunya Fever Pipeline Overview

The Q4 Chikungunya Fever pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Chikungunya Fever, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Chikungunya Fever Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Chikungunya Fever disease overview, Chikungunya Fever types, Chikungunya Fever symptoms, causes, and FDA/EMA approved treatment options.

Chikungunya Fever Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Chikungunya Fever indication. The report presents near-term and long-term pipeline development trends and potential insights.

Chikungunya Fever Company Trends and Insights

The report analyzes the development progress, current status, investments, partnerships, and other developments of 32 companies. Business profiles and contact details of the companies actively perusing Chikungunya Fever pipeline are assessed.

Chikungunya Fever R&D Pipeline Development Phase Trends and Insights

From the discovery stage of development to phase 3 development, all the potential

pipeline drug candidates are analyzed in the report. Chikungunya Fever discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Chikungunya Fever companies look for licensing and collaboration partners. High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Chikungunya Fever pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Chikungunya Fever Pipeline Market News and Developments during 2020

The Chikungunya Fever industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Chikungunya Fever Mechanism of Action and Targets

Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Sources and Research Methodology

Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

Scope and Coverage

Chikungunya Fever pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates

Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.

Company-company partnerships, company-institute partnerships, and

investment details of companies are included

32 companies are included including Bharat Biotech International Ltd, Bow Therapeutics, Ciloa, Emergent BioSolutions Inc, Emergex Vaccines Ltd, Ennaid Therapeutics LLC, Etubics Corporation, Hawaii Biotech Inc, HSRx Group, Imophoron Ltd, Indian Immunologicals Ltd, Inovio Pharmaceuticals Inc, Integral Molecular Inc, Integrated BioTherapeutics Inc, Medigen Inc, Moderna Therapeutics Inc, Najit Technologies Inc, Pai Life Sciences Inc, Paradigm Biopharmaceuticals Ltd, Precision Virologics Inc, Profectus BioSciences Inc, ProInhi BV, Riboscience LLC, Ridgeback Biotherapeutics LP, Sementis Ltd, Shionogi & Co Ltd, Takeda Pharmaceutical Co Ltd, Themis Bioscience GmbH, Valneva SE, Vaxart Inc, VenatoRx Pharmaceuticals Inc, Singapore Immunology Network,

Disease overview, Pipeline trends, market analysis, and other developments

Potential licensing/new business opportunities in Chikungunya Fever pipeline market

Highlights

Global coverage of companies and pipeline agents

2020 Trends, market analysis, and developments

Potential growth opportunities

Comprehensive details of drug candidates

Reasons to Buy

Drive pipeline research and commercial assessment

Assess most promising drug candidates and stay ahead of the competition

Strengthen your pipeline through identifying business expansion and acquisition opportunities

Develop new candidates based on most focused targets and mechanism of actions

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. CHIKUNGUNYA FEVER PIPELINE TRENDS AND INSIGHTS

- 2.1 Dominant Phase type of Chikungunya Fever Pipeline, 2020
- 2.2 Most focused Mechanism of Action in Chikungunya Fever Pipeline
- 2.3 Leading type of Route of Administration during 2020
- 2.4 Proportion of New Molecular Entities in Chikungunya Fever pipeline
- 2.5 Active Companies Developing Chikungunya Fever pipeline

3. CHIKUNGUNYA FEVER DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS

- 3.1 Disease Overview
- 3.2 Types
- 3.3 Symptoms
- 3.4 Approved Treatment Options

4. CHIKUNGUNYA FEVER PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS

- 4.1 Bharat Biotech International Ltd
 - Bov Therapeutics
 - Ciloa
 - Emergent BioSolutions Inc
 - Emergex Vaccines Ltd
 - Ennaid Therapeutics LLC
 - Etubics Corporation
 - Hawaii Biotech Inc
 - HSRx Group
 - Imophoron Ltd
 - Indian Immunologicals Ltd
 - Inovio Pharmaceuticals Inc
 - Integral Molecular Inc

Integrated BioTherapeutics Inc
Medigen Inc
Moderna Therapeutics Inc
Najit Technologies Inc
Pai Life Sciences Inc
Paradigm Biopharmaceuticals Ltd
Precision Virologics Inc
Profectus BioSciences Inc
ProtInhi BV
Riboscience LLC
Ridgeback Biotherapeutics LP
Sementis Ltd
Shionogi & Co Ltd
Takeda Pharmaceutical Co Ltd
Themis Bioscience GmbH
Valneva SE
Vaxart Inc
VenatoRx Pharmaceuticals Inc
Singapore Immunology Network

5. CHIKUNGUNYA FEVER PIPELINE DRUG PROFILES

5.1 Current Status of Drug and Vaccine Candidates

5.2 Drug Snapshot

5.2.1 Drug

5.2.2 Mechanism of Action

5.2.3 Phase

5.2.4 Co-Developer

5.2.5 Originator

5.2.6 Synonym

5.2.7 Route of Administration

5.2.8 Type of Molecule

5.2.9 Orphan Drug Status

5.2.10 New Molecular Entity

5.2.11 Area

5.3 Drug Details

5.4 Mechanism of Action

5.5 Licensing/Collaboration Agreements

5.6 Clinical Trial Details

6. CHIKUNGUNYA FEVER PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020

7. APPENDIX

7.1 About the Publisher

7.2 Sources and Research Methodology

I would like to order

Product name: Chikungunya Fever R&D Pipeline Analysis Report, Q4 2020

Product link: <https://marketpublishers.com/r/C9054E303A88EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C9054E303A88EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970